Brian Thiessen

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert, Monika E. Hegi, Martin J. van den Bent et al. · The Lancet Oncology · 2016 · 485 citations · Full text

Neuro-oncology, Glioma, Radiation Therapy +10

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

James Perry, Karl Bélanger, Warren Mason et al. · Journal of Clinical Oncology · 2010 · 380 citations

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

Brian Thiessen, Clinton F. Stewart, Ming‐Sound Tsao et al. · Cancer Chemotherapy and Pharmacology · 2009 · 200 citations

Oncology, Molecular Correlation, Medicine +10

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Jaap C. Reijneveld, Corneel Coens, Jacoline E. C. Bromberg et al. · The Lancet Oncology · 2016 · 130 citations

Quality Of Life, Life Assessment, Glioma +11